GlassScriptPhysician profile
Cierra Danielle Brown
NPI 1578130738
$4,482.15
in general payments reported to CMS, 2019-2025
38 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.53 · 2023: $1,689 · 2024: $1,534 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,465.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $916.31 | 2022-2025 | |
| Lilly USA, LLC | $568.70 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $430.44 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $425.31 | 2023-2025 | |
| Glaxosmithkline, LLC. | $175.01 | 2023-2025 | Shingrix, Bexsero, Arexvy |
| Pfizer INC. | $164.08 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $153.37 | 2025 | Jornay Pm |
| Amgen INC. | $140.72 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $132.01 | 2023-2024 | Xarelto |
| Idorsia Pharmaceuticals US INC | $98.12 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $94.53 | 2023-2025 | Trintellix, Gattex |
| Ironshore Pharmaceuticals INC. | $89.75 | 2023-2024 | Jornay Pm |
| Novo Nordisk INC | $86.71 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi Pasteur INC. | $86.19 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $75.90 | 2025 | Voquezna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.19 | 2023-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $70.98 | 2023 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $70.18 | 2025 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.10 | 2023-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $66.01 | 2023-2024 | Nexletol |
| Cranial Technologies, INC | $55.16 | 2023-2024 | Doc Band |
| Exact Sciences Corporation | $48.67 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $47.05 | 2025 | Rexulti |
| Corcept Therapeutics | $43.93 | 2025 | Korlym |
| Boston Scientific Corporation | $33.87 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Vivus LLC | $31.91 | 2023 | Qsymia, Pancreaze |
| Lundbeck LLC | $29.18 | 2025 | Vyepti |
| Tris Pharma INC | $24.97 | 2024 | Dyanavel Xr |
| Biomarin Pharmaceutical INC. | $23.94 | 2024 | Voxzogo 1.2mg |
| Neurelis, INC. | $20.75 | 2023 | Valtoco |
| Merck Sharp & Dohme LLC | $19.48 | 2025 | Capvaxive |
| Seqirus USA INC | $18.83 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Inari Medical, INC. | $17.86 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Regeneron Healthcare Solutions, INC. | $16.97 | 2023 | Evkeeza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.28 | 2024 | Caplyta |
| Organon LLC | $16.10 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.40 | 2025 | Eliquis |
| Nevro Corp. | $13.19 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cierra Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.